{"filings":[{"id":99839,"accession_number":"0000926326-26-000009","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omnicell Q1 revenue $310M (+15% YoY); raises FY2026 non-GAAP EBITDA/EPS guidance","event_type":"earnings","confidence":"high","bullets":["GAAP net income $11M ($0.25/diluted) vs loss of $7M ($0.15 loss) in Q1 2025.","Non-GAAP net income $25M ($0.55/diluted); Non-GAAP EBITDA $45M, vs $24M a year ago.","Operating cash flow $55M, more than double the $26M in Q1 2025.","FY2026 revenue guidance raised to $1.215B–$1.255B; non-GAAP EPS raised to $1.80–$2.00.","Customer engagement underway for Titan XT and OmniSphere platform evolution."],"consensus_eps_estimate":null,"consensus_eps_actual":0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":309880000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116092,"accession_number":"0000926326-26-000003","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omnicell Q4 rev $314M (+2% YoY), GAAP net loss $0.05/sh; FY26 revenue guide $1.215-1.255B","event_type":"earnings","confidence":"high","bullets":["Q4 total revenues $314M (+2% YoY); full-year 2025 rev $1.185B (+7% YoY).","GAAP net loss Q4 $2M ($0.05 diluted loss) vs net income $16M ($0.34) in Q4 2024.","Non-GAAP net income Q4 $18M ($0.40) vs $28M ($0.60) YoY; FY25 non-GAAP EPS $1.62.","FY2025 product bookings $535M (-4% YoY); ARR $635.6M (+9.6%); product backlog $640.3M.","Launched Titan XT dispensing system at ASHP Midyear; guides FY26 rev $1.215-1.255B, Non-GAAP EBITDA $145-160M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":1184845000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132529,"accession_number":"0001104659-25-119083","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Omnicell launches Titan XT automated dispensing system powered by OmniSphere cloud platform","event_type":"other_material","confidence":"high","bullets":["Launch of Omnicell Titan XT, a next-gen automated dispensing system for autonomous medication management, available now in US.","Powered by OmniSphere cloud platform, unifying automation and AI-enabled intelligence for enterprise-wide medication management.","Features include DynamicRestock guided workflows, centralized inventory control, and AI predictive stock risk analytics.","Designed to improve pharmacy control and nursing confidence with FiveRights safeguards and simplified medication retrieval.","International availability anticipated in later 2026; ongoing OmniSphere releases beginning early 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132528,"accession_number":"0000926326-25-000029","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omnicell Q3 rev $311M (+10% YoY), beats guidance; raises FY2025 outlook","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $311M (+10% YoY); GAAP EPS $0.12, non-GAAP EPS $0.51; non-GAAP EBITDA $41M.","Results exceeded prior Q3 guidance; full-year revenue guidance raised to $1.177B-$1.187B.","Non-GAAP EBITDA guidance raised to $140M-$146M; non-GAAP EPS raised to $1.63-$1.73.","Repaid $175M convertible notes; repurchased ~1.987M shares for $62M during Q3.","Cash $180M, debt $167M; operating cash flow $28M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":870861000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132527,"accession_number":"0000926326-25-000026","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Omnicell adopts amended bylaws with enhanced stockholder nomination and proposal procedures","event_type":"other","confidence":"high","bullets":["Board adopted fourth amended and restated bylaws effective September 30, 2025.","Enhanced disclosure requirements for stockholder director nominations and proposals (excluding Rule 14a-8).","Addresses Rule 14a-19 requirements and clarifies personal jurisdiction consent.","Includes ministerial and conforming updates."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149060,"accession_number":"0001104659-25-082526","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Omnicell appoints Baird Radford as CFO effective Aug 26; Etta steps down","event_type":"leadership","confidence":"high","bullets":["Baird Radford appointed EVP and CFO effective August 26, 2025; succeeds Nchacha Etta who steps down.","Radford brings 30+ years in healthcare/tech; most recently CFO at Allakos; also CFO at HeartFlow.","Nchacha Etta will remain as executive adviser through November 15, 2025 to ensure smooth transition.","Compensation: base salary $525,000; one-time RSU grant of $1,000,000; annual equity target of $2,300,000 in RSUs and PSUs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149059,"accession_number":"0000926326-25-000016","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Omnicell Q2 2025 revenue $291M (+5% YoY), beats guidance; raises FY2025 outlook","event_type":"earnings","confidence":"high","bullets":["Total revenues $291M (+5% YoY); GAAP EPS $0.12, non-GAAP EPS $0.45.","Non-GAAP EBITDA $38M; operating cash flow $43M in Q2 2025.","FY2025 total revenue guidance raised to $1.130B-$1.160B; non-GAAP EPS raised to $1.40-$1.65.","Product bookings guidance reaffirmed at $500M-$550M; ARR $610M-$630M.","Cash $399M, total debt $342M; $350M revolver undrawn as of June 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":560230000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168032,"accession_number":"0001104659-25-056908","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Omnicell CFO Nchacha Etta separation agreement provides $925K severance, extended departure to Nov 15, 2025","event_type":"leadership","confidence":"high","bullets":["CFO Nchacha Etta to depart; employment extended through Nov 15, 2025, or until successor appointed.","Severance of $925,062 (12 months base salary + target bonus) plus $10,000 for outplacement.","Additional one year vesting credit on equity awards; 12 months continued financial planning ($16k/year max).","Etta to serve as Special Advisor to CEO after successor named or transition to advisory role.","Agreement includes standard restrictive covenants and general release of claims."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168031,"accession_number":"0001104659-25-052464","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Omnicell stockholders approve 1.75M share increase to 2009 equity plan; re-elect directors","event_type":"other","confidence":"high","bullets":["Stockholders elected Edward P. Bousa, Mary Garrett, and Bruce E. Scott as Class III directors for three-year terms.","Amendment to 2009 Equity Incentive Plan approved: adds 1,750,000 authorized shares to common stock pool.","Say-on-pay advisory vote passed with 35.78M for vs 1.72M against; auditor Deloitte ratified with 41.53M for.","Broker non-votes of 4.28M recorded on director election and advisory items.","Plan amendment filed as Exhibit 10.1; full terms incorporate proxy statement Appendix A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168030,"accession_number":"0001104659-25-051854","cik":926326,"company_name":"OMNICELL, INC.","ticker":"OMCL","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Omnicell raises Q2 and FY2025 profit outlook on tariff relief; authorizes $75M share buyback","event_type":"earnings","confidence":"high","bullets":["Q2 Non-GAAP EBITDA guidance raised to $25-31M (from $22-30M); Non-GAAP EPS raised to $0.24-0.34 (from $0.19-0.32).","FY2025 Non-GAAP EBITDA low end raised to $120M (from $100M); Non-GAAP EPS low end raised to $1.30 (from $1.00).","Revenue guidance unchanged: FY total revenue $1.105-1.155B, Q2 total $270-280M.","Board authorized new $75M stock repurchase program with no expiration; $2.7M remains under prior 2016 program.","Improvement attributed to U.S. tariff reduction on China imports from 145% to 30% for 90 days."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":269668000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}